Arthritis clinical trials at UCSF
8 in progress, 4 open to eligible people

  • Multimodal Sleep Pathway for Shoulder Arthroplasty

    open to eligible people ages 18 years and up

    The purpose of the study is to investigate the efficacy of sleep medicine in the recovery of orthopaedic shoulder arthroplasty patients. The investigators hypothesize that a multimodal sleep pathway including non-pharmacological sleep hygiene interventions and the use of zolpidem can improve patient sleep, pain control, and subsequent recovery after undergoing total shoulder arthroplasty.

    San Francisco, California

  • Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis

    open to eligible people ages 18 years and up

    The purpose of this study is to determine if hydroxychloroquine (HCQ) is safe and effective for the prevention of future onset of rheumatoid arthritis (RA) in individuals who have elevations of an autoantibody, anti-cyclic citrullinated peptide (anti-CCP3). The following recruitment strategies will be employed towards identifying healthy subjects with elevated anti-cyclic citrullinated peptide (anti-CCP3) levels: -Pre-screening: - first degree relatives of patients with rheumatoid arthritis (RA); - subjects at health-fairs; and - identification of subjects with elevated anti-CCP3 levels in the absence of inflammatory arthritis in rheumatology clinics.

    San Francisco, California and other locations

  • Treatments Against RA and Effect on FDG-PET/CT

    open to eligible people ages 45 years and up

    In a randomized controlled clinical trial, investigators will compare the effects on [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) from two treatment regimens in rheumatoid arthritis (RA) patients deemed methotrexate inadequate responders (MTX-IRs). Two common RA treatments will be compared: triple therapy (sulfasalazine, methotrexate, and hydroxychloroquine) versus tumor necrosis factor (TNF) inhibitor (etanercept or adalimumab, plus background methotrexate for all subjects and hydroxychloroquine for subjects who were taking this at screening).

    San Francisco, California and other locations

  • Zr-89 Cimzia PET Imaging Rheumatoid Arthritis

    open to eligible people ages 18 years and up

    This is a single center exploratory imaging study investigating the initial application of 89Zr-DFO-CZP PET in patients with rheumatoid arthritis. Patients with active symptoms of RA or signs on physical exam will be invited to participate for PET imaging.

    San Francisco, California

  • Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty

    Sorry, in progress, not accepting new patients

    The objectives of this study are to obtain survival and outcome data on the Trabecular Metal Reverse Shoulder System when used in primary or revision reverse total shoulder arthroplasty.

    San Francisco, California and other locations

  • Pediatric Arthritis Study of Certolizumab Pegol

    Sorry, in progress, not accepting new patients

    A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).

    San Francisco, California and other locations

  • Sidus Stem-Free Shoulder IDE Study

    Sorry, in progress, not accepting new patients

    The purpose of this study is to determine if Sidus stem-free shoulder system is safe and effective when used in total shoulder replacement.

    San Francisco, California and other locations

  • Start Time Optimization of Biologics in Polyarticular JIA

    Sorry, in progress, not accepting new patients

    STOP-JIA is a PCORI funded prospective observational study which will compare the clinical effectiveness and impact on patient reported outcomes of 3 Childhood Arthritis & Rheumatology Research Alliance (CARRA) consensus derived treatment strategies (CTPs) in new-onset polyarticular JIA (pJIA) patients to answer the critical question of when is the best time to begin biologic medications to achieve the optimal clinical and patient reported outcomes. Because the CARRA Registry will be used for data collection, all patients will be enrolled in the CARRA Registry. The standard of care treatments are chosen by the treating physician and patient/caregiver and are not randomized.

    San Francisco, California and other locations

Last updated: